Prilosec OTC Exceeds Sales Expectations, Drags Down Healthcare Earnings
This article was originally published in The Tan Sheet
Executive Summary
Prilosec OTC sales have been a boon to Procter & Gamble's healthcare top line, but the product's successful launch has negatively impacted earnings a year after its debut
You may also be interested in...
P&G Thinks Globally, Acts Locally With Long-Term Growth Strategy
Procter & Gamble has its eye on broadening its reach in key developing markets as it pursues its comprehensive global growth strategy
Prilosec OTC Sales Top The $400 Mil. Mark; Prevacid Feeling The Burn
Abbott says that Prilosec OTC continues to eat into Prevacid sales and the overall prescription proton pump inhibitor category after one year on the market
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC